FunPep Past Earnings Performance
Past criteria checks 0/6
FunPep has been growing earnings at an average annual rate of 20.4%, while the Biotechs industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 100% per year.
Key information
20.4%
Earnings growth rate
35.1%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -100.0% |
| Return on equity | -40.5% |
| Net Margin | n/a |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How FunPep makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -933 | 267 | 680 |
| 31 Dec 22 | 1 | -1,172 | 222 | 912 |
Quality Earnings: 4881 is currently unprofitable.
Growing Profit Margin: 4881 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 4881's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 4881's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4881 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4881 has a negative Return on Equity (-40.55%), as it is currently unprofitable.